Products
PRODUCTS
Nilatinib Maleate
Summary:
It is indicated for adult patients with human epidermal growth factor receptor 2(HER2)-positive early-stage breast cancer after intensive adjuvant therapy with trastuzumab.
File:
NMPA API Registration No.: Y20210001042
Application:
Commercialization
Indications:
Tyrosine kinase inhibitors
Key words:
Classification:
APIs
Product Details
|
Product Name
|
Lainatinib maleate
|
|
CAS No.
|
915942-22-2
|
|
Molecular formula
|
C34H33ClN6O7
|
|
molecular weight
|
673.115
|
|
Product Structure
|
 |
Related Products
online message
If you have any questions, please leave a message here and leave your contact information. We will reply to you as soon as possible.
